In Brief: A Second Indication for Tucatinib (Tukysa)
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1670g ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Oxazoles, Pyridines.
Abstract (Originalsprache)
The oral kinase inhibitor tucatinib (Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine (Xeloda, and generics) for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who received at least one prior anti-HER2-based regimen for metastatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). In Brief: A Second Indication for Tucatinib (Tukysa). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670g
Vancouver
In Brief: A Second Indication for Tucatinib (Tukysa). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670g
BibTeX
@article{euvimed2023,
title = {In Brief: A Second Indication for Tucatinib (Tukysa)},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1670g}
}
EUVIMED